#USA #New York #Pomerantz LLP #Fortress Biotech #FBIO

Pomerantz Law Firm Investigates Fortress Biotech Inc. on Behalf of Investors

Pomerantz LLP, a prominent law firm known for its expertise in securities, corporate, and antitrust class litigation, has launched an investigation into Fortress Biotech Inc. This inquiry is aimed at evaluating claims from investors regarding possible securities fraud and other illegal business practices by the company and its executives.

On October 1, 2025, Fortress Biotech and its subsidiary, Cyprium Therapeutics Inc., announced receiving a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) concerning their New Drug Application for CUTX-101. The letter highlighted significant deficiencies pertaining to Current Good Manufacturing Practices (cGMP) at the production facility of CUTX-101, raising concerns about the drug's manufacturing standards.

As a direct consequence of this news, Fortress Biotech experienced a staggering decline in its stock price, plummeting $1.14 per share, equivalent to a 30.81% drop, and closing at $2.56 per share on that same day. This fallout has prompted widespread concern among investors and stakeholders.

Given the substantial financial losses reported by investors, Pomerantz LLP urges individuals affected by this situation to reach out. The firm's contact, Danielle Peyton, can be reached at [email protected] or via phone at 646-581-9980, ext. 7980. This investigation seeks to ascertain whether Fortress Biotech and its management engaged in misconduct or misled investors about the company's standing and potential risks, particularly in light of regulatory actions by the FDA.

Founded by Abraham L. Pomerantz, a pivotal figure in class action litigation, Pomerantz LLP has a rich history of representing clients in securities fraud cases. Their relentless commitment to upholding investor rights and holding companies accountable for their actions has enabled them to recover numerous multimillion-dollar settlements for aggrieved investors. With offices spread across major cities including New York, Chicago, London, and Tel Aviv, the firm has established itself as a leader in litigating claims of securities fraud and breaches of fiduciary duties.

As the investigation unfolds, the implications for Fortress Biotech may extend beyond financial implications. Should this inquiry reveal any misconduct, it could lead to significant legal repercussions for the company's executives and impact its operational viability in the long run. Therefore, both current and former investors are recommended to monitor the situation closely and consider participating in the potential class action.

Furthermore, Pomerantz' track record of recovery reinforces their capability and commitment to compensate investors who may have suffered losses due to corporate malpractice. If you're an investor in Fortress Biotech, it is crucial to stay informed and proactive about your investments and rights.

For continual updates regarding this investigation, please refer to official channels, including Pomerantz’s website, and follow legal developments closely pertaining to Fortress Biotech. Investors are also encouraged to consult legal advice to understand their rights and options moving forward.

In conclusion, Fortress Biotech finds itself at a regulatory crossroads, and with Pomerantz Law Firm's investigation underway, the outcome will be pivotal in determining the potential liabilities of the company and the safeguarding of investors' interests.